Poseida Therapeutics Receives FDA Orphan Drug Designation For Ornithine Transcarbamylase Deficiency Treatment
Portfolio Pulse from Happy Mohamed
Poseida Therapeutics has received FDA Orphan Drug Designation for its treatment of Ornithine Transcarbamylase Deficiency. This designation provides certain benefits including tax credits, market exclusivity for seven years, and exemption from certain FDA fees.
July 31, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics' FDA Orphan Drug Designation for its treatment could provide financial benefits and market exclusivity, potentially boosting its stock.
The FDA Orphan Drug Designation provides several benefits including tax credits, market exclusivity for seven years, and exemption from certain FDA fees. These benefits could lead to increased profitability for Poseida Therapeutics, potentially leading to a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100